TABLE 3.
Outcomes according to surveillance phenotypes
| Outcome | All (n = 441) | SCI (n = 137) | NMA (n = 304) | P | ||
|---|---|---|---|---|---|---|
| SC-B-TCMR (n = 102) | SC-TCMR (n = 15) | SC-MVI (n = 20) | ||||
| Triple composite endpoint, n (%) | 30 (7) | 14 (14) | 0 (0) | 5 (25) | 11 (4) | 0.0001 |
| Acute rejection after surveillance, n (%) | 16 (4) | 8 (8) | 0 (0) | 3 (15) | 5 (2) | 0.001 |
| TCMR | 4 (1) | 3 (3) | 0 (0) | 0 (0) | 1 (0.3) | 0.01 |
| AMR/mixed | 12 (3) | 5 (5) | 0 (0) | 3 (15) | 4 (1) | |
| Death-censored graft failure, n (%) | 10 (2) | 7 (7) | 0 (0) | 2 (10) | 1 (0.3) | 0.0002 |
| Death, n (%) | 9 (2) | 2 (2) | 0 (0) | 1 (5) | 6 (2) | 1.00 |
| Estimated GFR (mL/min/1.73 m2), 12 mo | 49 ± 0.6 (n = 388) | 54 ± 2 | 47 ± 4 | 55 ± 5 | 58 ± 1 | 0.06 |
| Estimated GFR (mL/min/1.73 m2), 24 mo | 49 ± 0.6 (n = 238) | 57 ± 3 | 49 ± 4 | 55 ± 7 | 58 ± 2 | 0.26 |
| Estimated GFR decline >30%, 6–24 mo, n (%) | 16/238 (7) | 3 (6) | 1 (14) | 0 (0) | 12 (7) | 0.78 |
Comparison of outcomes after the 6-mo surveillance biopsy. The first column shows outcomes for the entire cohort. The P represent comparisons between the SCI group and the NMA group by Mann-Whitney U test (continuous variables) or chi-square/Fisher exact test (categorical variables). Non-normally distributed continuous variables are presented as mean ± SE.
AMR, antibody-mediated rejection; GFR, glomerular filtration rate; NMA, no major surveillance abnormalities; SC-B-TCMR, subclinical borderline T cell-mediated rejection; SCI, subclinical inflammation; SC-MVI, subclinical microvascular injury; SC-TCMR, subclinical T cell-mediated rejection; TCMR, T cell-mediated rejection.